Clinical trial Recruiting at 1 site Interventional Ages 18 to 60 Women only

Using autologous blood transfusion with stem cells to protect bone marrow in cervical cancer patients

Official title: Stored Hematopoietic Stem Cell-containing Autologous Blood Transfusion Therapy for Bone Marrow Protection in Patients With Cervical Cancer Treated With Concurrent Chemoradiotherapy

Run by Chongqing University Cancer Hospital · NCT05401175 · Data updated 2026-11-12

This study is testing if giving cervical cancer patients their own blood with stem cells after treatment can help them recover their blood cell production faster and better than standard care.

More Cervical Cancer trials

Quick facts

Study typeInterventional
Ages18 Years to 60 Years
SexWomen only
Enrollment40 (estimated)
SponsorChongqing University Cancer Hospital
Academic / other
Drugs / interventionschemotherapy
Locations1 site (Chongqing, Chongqing Municipality)
StatusRecruiting
StartedApril 13, 2022
Main results expectedApril 2027
Study endsApril 2029
Registry record updatedJune 29, 2026
Trial IDNCT05401175 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are pre-menopausal women aged 18-60 with a confirmed diagnosis of cervical cancer who are eligible for concurrent chemoradiotherapy.

Probably not a fit

Patients with existing bone marrow diseases or those with metastases to the central nervous system or bone marrow are unlikely to benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This project aims to enhance the recovery of hematopoietic function following chemoradiotherapy in cervical cancer patients through the innovative use of autologous blood transfusions containing hematopoietic stem cells. In a prospective, single-center, non-randomized controlled design, patients will be divided into two groups: one receiving the stem cell transfusion after treatment and the other receiving standard care. The study will monitor the incidence and duration of severe neutropenia and the time taken for hematopoietic recovery, alongside evaluating safety and other secondary endpoints related to treatment delays and adverse events.

Why it matters

Potential benefit: If successful, this approach could significantly improve bone marrow recovery and overall treatment outcomes for cervical cancer patients undergoing chemoradiotherapy.

How similar studies have gone: While the use of stem cell support in cancer treatment is established, the specific application of autologous blood transfusion for bone marrow protection in cervical cancer is relatively novel and has not been extensively tested.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1)18-60 years old; 2)there are radiotherapy and chemotherapy indicators for cervical cancer;3)pathological diagnosis of squamous, adenocarcinoma or adenosquamous carcinoma;4)the Eastern Cooperative Oncology Group (ECOG) performance status score≤1; 5)the expected survival time was more than 3 months; 6)pre-menopausal women (post-menopausal women must have been postmenopausal for at least 12 months to be considered infertile), and the serum pregnancy test results are negative;7)all patients must agree to take effective contraceptive measures during the study period and within 6 months after stopping treatment;8)the subjects voluntarily participate in this clinical trial sign an informed consent form and are able to complete the study procedures and follow-up examinations.

Exclusion Criteria:

1\) clinical diagnosis of bone marrow disease;2) imaging or pathological diagnosis of central nervous system or soft meningeal or bone or bone marrow metastases;3)patient has severe cardiac insufficiency;4)previous history of allogeneic stem cell transplantation or organ transplantation;5)patients with active bleeding and autoimmune thrombocytopenic purpura;6)patients with radiochemotherapy contraindications;7)positive for human immunodeficiency virus (HIV);8)acute or chronic active hepatitis B or hepatitis C infection;9)History of gastrointestinal perforation and/or fistula, clinical signs or symptoms of intestinal obstruction and/or gastrointestinal obstruction (including incomplete intestinal obstruction requiring parenteral nutrition), inflammatory bowel disease or extensive bowel resection (partial colectomy or extensive small bowel resection complicated by chronic diarrhoea), Crohn's disease, ulcerative colitis or chronic diarrhoea within the previous 6 months;10)evidence of an intra-abdominal pneumoperitoneum that cannot be explained by puncture or recent surgical intervention.

Where it's running

  • Chongqing University Cancer Hospital
    Chongqing, Chongqing Municipality, China
    Recruiting

Study contacts

  • Principal investigator: Dongling Zou, M.D. — Chongqing University Cancer Hospital
  • Study coordinator: Dongling Zou, M.D.
  • Email: cqzl_zdl@163.com
  • Phone: 13657690699

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.